Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2016-07-18 AGM Information
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Result of AGM
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) from the London Stock Exchange's RNS service. It explicitly states the 'Result of AGM' regarding the reappointment of auditors. While it relates to an AGM, it is a formal declaration of the voting outcome rather than the full presentation materials, making it a Declaration of Voting Results.
2016-07-18 English
BPS-804 granted EU orphan drug status
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details a specific corporate development—the granting of orphan drug status for a product candidate—which does not fall into specialized categories like financial reports, dividends, or M&A. As it is a general corporate announcement regarding regulatory milestones, it is classified as a Regulatory Filing (RNS).
2016-06-30 English
Notice of AGM
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from the London Stock Exchange's RNS service. It explicitly states that the 'Notice of Annual General Meeting' and 'Form of Proxy' have been sent to shareholders and are available on the company's website. According to the 'Menu vs Meal' rule, this is an announcement regarding the publication of materials rather than the materials themselves, making it a Report Publication Announcement (RPA).
2016-06-24 English
Director/PDMR Shareholding
Director's Dealing Classification · 95% confidence The document is an RNS announcement regarding the 'Grant of Options' to specific directors (CEO and CFO) of Mereo BioPharma Group plc. While it mentions remuneration, it is specifically an announcement of a grant of share options to directors, which falls under the category of Director's Dealing (DIRS) as it reports personal share-related transactions/awards for company executives.
2016-06-09 English
First Day of Dealings on AIM
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding Mereo BioPharma Group plc's first day of dealings on the AIM market. It details the company's admission to trading, the capital raised, and the ticker symbol. Since this is a general regulatory announcement regarding a company's market debut and does not fit into specific categories like M&A or financial reporting, it is classified as a Regulatory Filing (RNS).
2016-06-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.